| |
Continuous (N=16)
|
Binary (N=65)
|
Ordinal (N=24)
|
Time-to-event (N=44)
|
Other (N=4)
|
|---|
|
Time frame
|
|
≤14 days
|
3 (18.8%)
|
12 (18.5%)
|
6 (25.0%)
|
3 (6.8%)
|
1 (25.0%)
|
|
15–30 days
|
10 (62.5%)
|
45 (69.2%)
|
18 (75.0%)
|
37 (84.1%)
|
2 (50.0%)
|
|
>30 days
|
3 (18.8%)
|
8 (12.3%)
|
0 (0.0%)
|
4 (9.1%)
|
1 (25.0%)
|
|
Evaluation of clinical course
|
|
Improvement
|
-
|
19 (29.2%)
|
-
|
34 (77.3%)
|
-
|
|
Worsening
|
-
|
39 (60.0%)
|
-
|
6 (13.6%)
|
-
|
|
Unknown
|
-
|
7 (10.8%)
|
-
|
4 (9.1%)
|
-
|
|
Sample size (trials with 1 arma)
|
| |
(N=5)
|
(N=10)
|
(N=4)
|
(N=15)
|
(N=1)
|
|
Mean (SD)
|
101.2 (56.4)
|
472.3 (407.3)
|
279.3 (226.1)
|
335.7 (274.5)
|
180 ( - )
|
|
Median (IQR)
|
76 (76, 76)
|
239 (197.8, 565.5)
|
223.5 (173.5, 329.3)
|
200 (140, 600)
|
180 ( - )
|
|
Sample size (trials with 2 armsa)
|
| |
(N=6)
|
(N=35)
|
(N=15)
|
(N=22)
|
(N=1)
|
|
Mean (SD)
|
420.7 (175.0)
|
577.0 (808.8)
|
476.3 (606.1)
|
498.4 (320.8)
|
600 ( - )
|
|
Median (IQR)
|
468 (341.5, 500)
|
376 (265, 530)
|
330 (100, 425)
|
409 (259.5, 677.5)
|
600 ( - )
|
|
Sample size (trials with ≥3 armsa)
|
| |
(N=5)
|
(N=20)
|
(N=5)
|
(N=7)
|
(N=2)
|
|
Mean (SD)
|
457.8 (498.2)
|
1124.0 (864.4)
|
850.0 (1271.8)
|
1199.1 (733.5)
|
109.5 (48.8)
|
|
Median (IQR)
|
189 (50, 1000)
|
1200 (283.5, 1770.5)
|
450 (100, 500)
|
1034 (750, 159)
|
109.5 (-)
|
- aA single drug with multiple doses that was placed under the same “Arm” in Interventions was considered as one arm
- SD standard deviation, IQR interquartile range
